MSX-122 Administered Orally in Patients With Refractory Metastatic or Locally Advanced Solid Tumors

Summary

Primary Objectives: 1. To determine the maximum tolerated dose (MTD) and the recommended Phase II dose(s) and schedule of MSX-122 2. To characterize the dose limiting toxicities (DLTs) and determine the overall safety and tolerability of MSX-122 Secondary Objectives: 1. To determine the pharmacokinetics and pharmacodynamics of orally administered MSX-122 2. To evaluate the preliminary evidence for anti-tumor activity of MSX-122 3. To perform correlative studies to elucidate signaling pathways involved in CXCR4 activation in blood and optional tissue specimens by IHC (immunohistochemistry) and RPPA (reverse phase protein microarrays)

Timeline

Start

2007-11

Primary completion

2008-12

Completion

2009-03

Drugs

Indications